Schott Pharma said it has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a range of drugs – from biologics and other complex injectable therapies to vaccines and emergency room medications.
The new capabilities feature technology for efficient manufacturing and optimized output. The more than $60 million investment was largely funded by the Biomedical Advanced Research and Development Authority (BARDA) to strengthen the resilience of the U.S. pharmaceutical supply chain and ensure reliable domestic production of critical primary packaging. The expansion increases the site’s annual production capacity for core vials, while more than tripling local capacity for high-value solutions.
“The expansion contributes to SCHOTT Pharma’s long-term global growth strategy, with a strong local-for-local presence in the U.S. and scaled manufacturing capacity for high-value solutions that address key trends in the pharmaceutical industry, such as biologic medications and novel drug formulations,” says Christian Mias, CEO of SCHOTT Pharma.
In addition to installing a number of new high-end converting lines for core borosilicate glass vials, the expansion in Lebanon included major infrastructure modernization, line upgrades and new technology to increase the capacity for high-value solutions. These include the RTU vial platform adaptiQ and EVERIC pure vials.
The Lebanon site is one of only two Schott Pharma locations worldwide capable of manufacturing EVERIC pure vials. It is also the only Schott Pharma site producing adaptiQ pre‑washed, pre‑sterilized RTU vials.
